V116 Elicits Noninferiority Immune Response Compared with PPSV23 for Pneumococcal Disease
Merck presented results from the STRIDE-10 phase 3 trial at the 34th European Society of Clinical Microbiology and Infectious Diseases in Barcelona, Spain.
Source: pharmacytimes.com